We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 425

Motion for default judgment denied without affidavit evidence
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

The Plaintiffs brought a motion for default judgment after no Statement of Defence was filed and no response to the Request to Admit was provided. The


Other industry news
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Health Canada has released of the Therapeutic Products Directorate Statistical Report 20122013 for the Patented Medicines (Notice of Compliance


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada, USA
  • May 22 2013

The Supreme Court has dismissed Eli Lilly of Canada Inc.’s leave on the issue, as summarized by the Court, as to whether the creation by the Federal


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • June 17 2013

Although the Court of Appeal had split 2-1, the Supreme Court refused Takeda's application for leave as well as the motion to intervene by Canada's


Final injunction permits existing patients to continue to receive infringing medicine
  • Borden Ladner Gervais LLP
  • Canada
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision


NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • March 25 2013

The Federal Court found Teva’s allegations of invalidity were not justified for Novartis’ narrow compound patent, while the allegations against


Clinical studies exempted from public use in allegation of anticipation
  • Borden Ladner Gervais LLP
  • Canada
  • June 10 2014

His is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting that it had issued an Order of


Appeal upholds dismissal of request to amend pleadings due to proximity to trial
  • Borden Ladner Gervais LLP
  • Canada
  • April 4 2014

This case concerns an appeal of a motion to amend pleadings in the s. 8 case described above. The motion had originally been brought three months


Patent infringement action dismissed since no claims were both valid and infringed
  • Borden Ladner Gervais LLP
  • Canada
  • June 2 2014

This was a patent infringement action, relating to an invention that pertains to the general field of building construction. The Court conducted a